|Title||Does active treatment in infants born at 22-23 weeks correlate with outcomes of more mature infants at the same hospital? An analysis of California NICU data, 2015-2019.|
|Publication Type||Journal Article|
|Year of Publication||2022|
|Authors||Bane S, Rysavy MA, Carmichael SL, Lu T, Bennett M, Lee HC|
|Date Published||2022 Oct|
|Keywords||Epinephrine, Female, Gestational Age, Hospitals, Humans, Infant, Infant Mortality, Infant, Newborn, Intensive Care Units, Neonatal, Intubation, Intratracheal, Pregnancy|
OBJECTIVE: To investigate whether hospital rates of active treatment for infants born at 22-23 weeks is associated with survival of infants born at 24-27 weeks.
STUDY DESIGN: We included all liveborn infants 22-27 weeks of gestation delivered at California Perinatal Quality Care Collaborative hospitals from 2015 to 2019. We assessed (1) the correlation of active treatment (e.g., endotracheal intubation, epinephrine) in 22-23 week infants and survival until discharge for 24-27 week infants and (2) the association of active treatment with survival using multilevel models.
RESULT: The 22-23 week active treatment rate was associated with infant outcomes at 22-23 weeks but not 24-27 weeks. A 10% increase in active treatment did not relate to 24-25 week (adjusted OR: 1.00 [95% CI: 0.95-1.05]), or 26-27 week survival (aOR: 1.02 [0.95-1.09]).
CONCLUSION: The hospital rate of active treatment for infants born at 22-23 weeks was not associated with improved survival for 24-27 week infants.
|Alternate Journal||J Perinatol|
|PubMed Central ID||PMC9522931|
|Grant List||R01 HD098287 / HD / NICHD NIH HHS / United States|